Roche reported it has rapidly developed a research-use-only PCR test targeting Bundibugyo Ebola virus to support response efforts amid an ongoing outbreak in the Democratic Republic of Congo and Uganda. Roche’s move follows recent commentary in The Lancet underscoring how limited or unreliable diagnostics can impede efforts to estimate outbreak scale and transmissibility for the strain. The company’s assay development adds to the immediate diagnostics toolkit being used alongside point-of-care platforms, with the aim of improving field and laboratory detection consistency as epidemiologic understanding evolves.